Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01077505 · ClinicalTrials.gov registry record · Phase 1
An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01077505 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 16 participants.
The verdict
NCT01077505, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will be an open-label study to evaluate the effect of albiglutide on the pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon). The primary objective of this study is to demonstrate the lack of effect of albiglutide doses on the pharmacokinetics of norethindrone and ethinyl estradiol in healthy female subjects.
Interventions
- BIOLOGICAL albiglutide
- DRUG Oral contraceptive (Brevicon)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-03-15 |
| Est. Completion | 2010-11-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01077505
The ClinicalTrials.gov registry entry for NCT01077505 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which albiglutide is the first listed.
NCT01077505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01077505 about?
NCT01077505 is a clinical study titled "An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .". This study will be an open-label study to evaluate the effect of albiglutide on the pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon). The primary objective of this study is to demonstrate the lack of effect of albiglutide doses on the pharmacokinetics of nore...
What is the current status of trial NCT01077505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-03-15. Estimated completion is 2010-11-24.
What interventions are being tested in trial NCT01077505?
The interventions under investigation include: albiglutide (BIOLOGICAL), Oral contraceptive (Brevicon) (DRUG).
Who is sponsoring clinical trial NCT01077505?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.